BTIG Research Cuts Insulet (NASDAQ:PODD) Price Target to $260.00

Insulet (NASDAQ:PODD) had its target price reduced by BTIG Research from $320.00 to $260.00 in a research note issued to investors on Wednesday morning, Marketbeat reports. They currently have a buy rating on the medical instruments supplier’s stock.

Several other brokerages have also commented on PODD. Royal Bank Of Canada reissued an “outperform” rating and issued a $325.00 price target on shares of Insulet in a report on Tuesday, April 14th. Truist Financial cut their price target on shares of Insulet from $360.00 to $315.00 and set a “buy” rating for the company in a report on Wednesday, April 15th. Sanford C. Bernstein cut their price target on shares of Insulet from $380.00 to $330.00 and set an “outperform” rating for the company in a report on Thursday, February 19th. Rothschild & Co Redburn reaffirmed a “neutral” rating and set a $220.00 target price (down from $380.00) on shares of Insulet in a research note on Friday, April 24th. Finally, Canaccord Genuity Group lowered their target price on shares of Insulet from $450.00 to $435.00 and set a “buy” rating on the stock in a research note on Wednesday, February 18th. Eighteen investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Insulet currently has a consensus rating of “Moderate Buy” and a consensus price target of $257.09.

Insulet Price Performance

NASDAQ:PODD opened at $154.16 on Wednesday. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.49 and a quick ratio of 2.15. The firm has a market cap of $10.68 billion, a price-to-earnings ratio of 35.85, a price-to-earnings-growth ratio of 0.92 and a beta of 1.20. The company has a 50 day moving average price of $211.22 and a 200-day moving average price of $263.85. Insulet has a 1-year low of $148.30 and a 1-year high of $354.88.

Insulet (NASDAQ:PODD) last posted its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, beating the consensus estimate of $1.19 by $0.23. The firm had revenue of $761.70 million during the quarter, compared to analyst estimates of $729.89 million. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The business’s quarterly revenue was up 33.9% on a year-over-year basis. During the same period in the previous year, the firm earned $1.02 EPS. Insulet has set its FY 2026 guidance at 6.210- EPS. Equities research analysts forecast that Insulet will post 6.46 EPS for the current year.

Insider Transactions at Insulet

In related news, Director Michael R. Minogue acquired 2,030 shares of Insulet stock in a transaction that occurred on Wednesday, February 25th. The shares were purchased at an average cost of $246.23 per share, for a total transaction of $499,846.90. Following the acquisition, the director owned 17,483 shares in the company, valued at approximately $4,304,839.09. This represents a 13.14% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 0.36% of the company’s stock.

Institutional Trading of Insulet

Several institutional investors and hedge funds have recently bought and sold shares of the stock. PNC Financial Services Group Inc. raised its holdings in Insulet by 2.1% in the 1st quarter. PNC Financial Services Group Inc. now owns 13,406 shares of the medical instruments supplier’s stock valued at $2,813,000 after buying an additional 274 shares during the period. Earned Wealth Advisors LLC purchased a new stake in Insulet during the first quarter worth about $236,000. Dimensional Fund Advisors LP increased its stake in Insulet by 4.0% during the first quarter. Dimensional Fund Advisors LP now owns 369,197 shares of the medical instruments supplier’s stock worth $77,470,000 after purchasing an additional 14,080 shares during the period. SEB Asset Management AB purchased a new stake in Insulet during the first quarter worth about $24,700,000. Finally, Swiss National Bank increased its stake in shares of Insulet by 7.1% during the first quarter. Swiss National Bank now owns 206,500 shares of the medical instruments supplier’s stock worth $43,332,000 after buying an additional 13,600 shares during the period.

Key Stories Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet’s Q1 results beat expectations, with revenue of $761.7 million and EPS of $1.42, and management raised full-year revenue growth guidance to 21%–23%, reinforcing momentum in its Omnipod diabetes platform.
• Positive Sentiment: The company highlighted strong international Omnipod growth and continued expansion of Omnipod 5 into new markets, which suggests the core business remains healthy. Article Title
• Neutral Sentiment: Recent earnings-call coverage and transcript coverage continued to emphasize improved profitability and upbeat management commentary following the Q1 report. Article Title
• Negative Sentiment: Multiple Wall Street firms cut price targets sharply after the earnings report, including Piper Sandler, JPMorgan, Citigroup, Wells Fargo, Stifel, Raymond James, Canaccord Genuity, Leerink, and others, which likely pressured the shares.
• Negative Sentiment: The stock is also trading well below several recent analyst targets, and the cluster of downgrades/target reductions may be signaling concerns about valuation or the pace of future upside despite the earnings beat.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.